JMP Securities Initiates Coverage On Assembly Biosciences with Market Outperform Rating, Announces Price Target of $38
Author: Benzinga Newsdesk | September 24, 2025 08:00am
JMP Securities analyst Roy Buchanan initiates coverage on Assembly Biosciences (NASDAQ:ASMB) with a Market Outperform rating and announces Price Target of $38.